Visiox Pharma Announces Close of $7M Seed Round
Summary
The proceeds enable Visiox to finalize and submit the NDAs for its lead assets, manufacture initial inventory, and add key talent as the company expands its commercial team. "The early positive response from the ophthalmic and optometric sectors further validates the physician and patient unmet needs that Visiox intends to serve in bringing its products to market," said Ryan Bleeks, Chief Executive Officer. "Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals.Visiox plans to submit two New Drug Applications to the U.S. FDA later this year in the glaucoma and cataract surgery markets. Our lead candidate, PDP-716, is a novel once daily brimonidine formulation utilizing our patented TearAct delivery technology, which provides slow, consistent, and sustained release for IOP control throughout the day.